Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Active-controlled, Parallel-group, Double-blind, Phase I Clinical Trial to Evaluate Safety and Immunogenicity of Hexavalent Vaccine (APV006) in Healthy Adults

NCT05952596 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT05952596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05952596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Active-controlled, Parallel-group, Double-blind, Phase I Clinical Trial to Evaluate Safety and Immunogenicity of Hexavalent Vaccine (APV006) in Healthy Adults
Lead sponsor
LG Chem
Phase
Phase 1
Overall status
Unknown status
Start date
July 17, 2023
Completion date
March 31, 2024
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b infection, hepatitis b, pertussis, poliomyelitis, tetanus